AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05432999 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Extracorporeal Shockwave Therapy
Description: Shockwaves are high pressure sound waves that interact with tissues to elicit a biological response. The shockwave probe will be placed on the skin with ultrasound gel and the muscle will be stimulated for a few minutes.
Study NCT05432999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy
Description: Shockwaves are high pressure sound waves that interact with tissues to elicit a biological response. The shockwave probe will be placed on the skin with ultrasound gel and the muscle will be stimulated for a few minutes.
Study NCT04629924 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sleeper one
Description: anesthesic injection with sleeper one device
Study NCT04629924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sleeper one
Description: anesthesic injection with sleeper one device
Study NCT04629924 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional technis
Description: anesthesic injection with the conventional technic
Study NCT04629924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional technis
Description: anesthesic injection with the conventional technic
Study NCT05029804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: This intervention will be applied to the patients in the experimental group. The education will be provided by the researcher and based on the transtheoritical model. Printed materials and PowerPoint presentations will be used for the education and the education will be conducted in a face-to-face session with each participant (10 weeks).
Study NCT05833776 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia using hyperbaric bupivacaine 0.5% (3ml) with fentanyl (25ug)
Description: group I (30 patients) received spinal anesthesia using hyperbaric bupivacaine 0.5% (3ml) with IPACK Block using plain bupivacaine 0.5% (15ml).
Study NCT05846308 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured synchronous physical training
Description: The instructors and the participants will form a circle facing each other while doing the physical exercises. To facilitate interpersonal synchrony, the participants will be instructed to do the same physical exercises (spatial synchrony) together at the same pace (rhythmic synchrony). Each session will consist of four parts:~1. Warm-up (10 minutes)~2. Social Game (10 minutes)~3. Main training (30 minutes): Each session will contain two sets, each consisting of seven fixed exercises with a resting period of 10-15 seconds between each. Each exercise will be performed at one of three different paces: Slow - one movement cycle per 2 seconds, Medium - one movement cycle per 1 second and Fast - two movement cycles per 1 second.~4. Cool-down (10 minutes)
Study NCT05846308 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured non-synchronous physical training
Description: The participants will do the same physical exercises as the participants in the synchronous group but in the form of circuit training with seven stations. The circuit training will require the participants to do a different physical exercise at a different pace at each station. A detailed description of the exercises will be provided for each station. The instructors will demonstrate all the exercises before the beginning of training. The participants will be instructed to do the exercise for a set period of time, the same duration used in the synchronous group. The circuit training stations will be in the form of a circle but will be set up so that the participants do not to face each other when doing the exercises to prevent spontaneous synchronization. Each session will consist of four parts, the same as in the synchronous intervention.
Study NCT05030675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Given PO
Study NCT05230030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improvisation Workshop
Description: Each improvisation workshop will involve a series of exercises derived from an improvisation game book previously developed by study investigators, followed by a reflective debrief of the experience.
Study NCT06413017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimtuzumab：400mg,i.v.,once a week,until tumor progression、Death or untalerable toxicity
Study NCT06413017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICIs(Immune checkpoint inhibitors)
Description: Use it as it is describe in the instructions from the specification
Study NCT06480877 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Taking a swab from periodontal pockets or gingival sulci
Description: Swabs for next generation sequencing were taken with paper points as described earlier.
Study NCT05021822 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Bilateral erector spinae plane block will be performed preoperatively under ultrasound guidance using 15 ml bupivacaine on each side
Study NCT05493228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precedex Injectable Product
Description: Precedex activates 2-adrenoceptors, and causes the decrease of sympathetic tone, with attenuation of the neuroendocrine and hemodynamic responses to anesthesia and surgery; it reduces anesthetic and opioid requirements; and causes sedation and analgesia. it is used before and/or during surgical
Study NCT05493228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: mixture of sodium chloride (salt) and water in solution with 0.90% w/v of NaCl
Study NCT05499143 — intervention group
Intervention type: OTHER
Intervention: Online questionnaire
Description: Online questionnaire impact for DCD - Belgian version
Study NCT05042362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: 120 mg elinzanetant orally once daily
Study NCT05042362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Elinzanetant (BAY3427080)
Description: 120 mg elinzanetant orally once daily
Study NCT05042362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo orally once daily
Study NCT06105996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interoceptive training
Description: There will be 6 interoceptive training sessions carried out over two months. Each training session will comprise two blocks, between which participants will undergo a self-paced, light physical activity that aims to enhance heartbeat perception and lasts 2 to 3 minutes. During the pre- and post-exercise block, each participant will complete cardiac interoceptive tasks, and for each trial, note their confidence in their answer on a visual analogue scale and then be given accurate feedback about their objective heartbeat perception accuracy and the accuracy of their subjective confidence rating, relative to their objective accuracy.
Study NCT05869383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ophiochepalus striatus extract
Description: Ophiochepalus striatus extract 2x5 grams
Study NCT05869383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2x5 grams
Study NCT06539416 — intervention group
Intervention type: PROCEDURE
Intervention: MitraClip implantation
Description: The MitraClip is used to catch the leaky parts of the mitral valve, and it is tested to ensure the leak is reduced.
Study NCT05212311 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chitosan Phonophoresis
Description: Therapeutic pulsed ultrasound using EMS physio Ltd ultrasound device in presence of chitosan gel will be applied over the elbow. The following parameters will be used: US treatment was applied for 5 min per session at a frequency of 3 MHz and an intensity of 0.5 W/cm2 in pulsed mode with a transducer area of 5 cm2.
Study NCT05212311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Ultrasound
Description: US treatment will be applied for 5 min per session at a frequency of 3 MHz and an intensity of 0.5 W/cm2 in pulsed mode with a transducer area of 5 cm2 using aquasonic gel.
Study NCT05212311 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splinting
Description: Splinting the elbow in comfortable flexion (40-70), forearm and wrist in neutral (slight forearm pronation and wrist flexion if symptoms are severe), can allow the nerve and surrounding supporting structures the rest and relief from compression and traction.~The elbow portion of the splint should be well padded or ''bubbled out'' to provide pressure relief for the area of the cubital tunnel. It may be necessary to splint the ulnar digits of the hand to prevent contracture, maintain passive and active range of motion, and improve hand function. If the motor branch of the nerve is sufficiently involved to cause muscle denervation, a hand-based intrinsic plus splint or the use of finger-based splints to prevent clawing of the ring and small fingers will provide balanced positioning of the affected structures.
Study NCT05212311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Splinting
Description: Splinting the elbow in comfortable flexion (40-70), forearm and wrist in neutral (slight forearm pronation and wrist flexion if symptoms are severe), can allow the nerve and surrounding supporting structures the rest and relief from compression and traction.~The elbow portion of the splint should be well padded or ''bubbled out'' to provide pressure relief for the area of the cubital tunnel. It may be necessary to splint the ulnar digits of the hand to prevent contracture, maintain passive and active range of motion, and improve hand function. If the motor branch of the nerve is sufficiently involved to cause muscle denervation, a hand-based intrinsic plus splint or the use of finger-based splints to prevent clawing of the ring and small fingers will provide balanced positioning of the affected structures.
Study NCT05212311 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neural mobilization exercises of the ulnar nerve
Description: Nerve mobilization exercises Inflammation or adhesions anywhere along the ulnar nerve path can cause the nerve to have limited mobility and essentially get stuck in one place. These exercises help stretch the ulnar nerve and encourage movement through the cubital tunnel
Study NCT05212311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mobilization exercises of the ulnar nerve
Description: Nerve mobilization exercises Inflammation or adhesions anywhere along the ulnar nerve path can cause the nerve to have limited mobility and essentially get stuck in one place. These exercises help stretch the ulnar nerve and encourage movement through the cubital tunnel
Study NCT06353802 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Chronic non-specific neck pain and lumbar reposition sense
Description: In order to evaluate the lumbar joint repositioning error using the Joint Positioning Sense, the following guidelines were followed: (I) The participants were to stand with their arms at their sides, their feet externally rotated (about 20 degrees).~(II) With the feet flat on the floor and the arms resting on the front of the thighs, the person was seated in a height-adjustable seat that measured the length of the shank. (III) With a belt fastened, the iPhone® was positioned upright just above the iliac crest, (IV) the inclination of the inclinometer was 0°; (V) The inclinometer's 0° point was set as the initial position. (VI) The individual was passively guided by the assessor to a 30° flexion within the range of 0 to 30°; (VII) the subject was to memorize this position for 10 s; (VIII) the subject actively returned to the initial position. (IX) Subsequently, the participant was required to actively replicate the position three times.
Study NCT06531811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8630 (test formulation) via test inhaler
Description: Participants will receive AZD8630 via test inhaler.
Study NCT06531811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8630 (reference formulation) via Monodose inhaler
Description: Participants will receive AZD8630 via Monodose inhaler.
Study NCT06531811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test inhaler
Description: Participants will receive AZD8630 via test inhaler.
Study NCT06531811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monodose inhaler
Description: Participants will receive AZD8630 via Monodose inhaler.
Study NCT06369883 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spine radiography
Description: Posterior-anterior and lateral spine radiography
Study NCT05277818 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery lumbar disc herniation
Description: Surgery for a degenerative or traumatic mono-segmental lumbar disc herniation
Study NCT06076798 — intervention group
Intervention type: DEVICE
Intervention: ECG co-measurement
Description: Measure ECG with 12 lead device at same time that AFGen1 is monitoring ECG
Study NCT06309485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WGI-0301 at MTD/RP2D dose IV infusion, QW
Description: WGI-0301 is a lipid nanoparticle preparation of Archexin®, a 20-mer oligonucleotide that is complementary to Akt-1 mRNA, formulated for the treatment of advanced HCC.
Study NCT06309485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WGI-0301 at MTD/RP2D -1 dose IV infusion, QW
Description: WGI-0301 is a lipid nanoparticle preparation of Archexin®, a 20-mer oligonucleotide that is complementary to Akt-1 mRNA, formulated for the treatment of advanced HCC.
Study NCT06309485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg PO, BID continuously
Description: Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.
Study NCT06309485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib 400 mg PO, BID continuously
Description: Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.
Study NCT06309485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg PO, BID
Description: Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.
Study NCT05063123 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Flotetuzumab
Description: Flotetuzumab will be given after at least 2 intensive chemotherapy cycles and before the start of the conditioning regimen prior to allo-HCT.
Study NCT04882033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy plus anlotinib
Description: Anlotinib: for cycle 1-6. P.O; QD; from days 1 to 14 in a 21-day cycle. 8mg in low-dose groups (3 subjects). 10mg in middle-dose groups (3 subjects). 12mg in high-dose groups (3 subjects).~Chemotherapy:~For cycle 1/4/5/6. Etoposide 100mg/m2, d1-3, q3w; Cisplatin 25mg/m2 d1-3, q3w. For cycle 2/3. Etoposide 50mg/m2, d1-3, q4w; Cisplatin 25mg/m2 d1-3, q4w.~Radiotherapy:~For cycle 2/3.Thoracic radiotherapy dose will be 2.0Gy per day, given 5 days a week, to cumulative dose of 60～66Gy.
Study NCT06505083 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: modified stepping trainings
Description: step-up on box texture difference
Study NCT06505083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modified stepping trainings
Description: step-up on box texture difference
Study NCT05801419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RETI-port/scan 21
Description: Pattern visual event-related potential and pattern electroretinogram on right eye (non-dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.
Study NCT05801419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilia Ocular
Description: Eye fundus tissue oximetry measure on left eye (dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.
Study NCT05801419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT-A
Description: Optical coherence tomography angiography measure on left eye (dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.
Study NCT05801419 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Electronic cigarette without nicotine
Description: Vaping using an e-cigarette paired with an e-cigarette liquid vial without nicotine. Inhaling through the mouth and exhaling through the nose ten times. Inhalations must last 5 seconds and the participant has 5 minutes to do the 10 inhalations.
Study NCT05801419 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Electronic cigarette with nicotine
Description: Vaping using an e-cigarette paired with an e-cigarette liquid vial with nicotine. Inhaling through the mouth and exhaling through the nose ten times. Inhalations must last 5 seconds and the participant has 5 minutes to do the 10 inhalations.
Study NCT06125067 — intervention group
Intervention type: PROCEDURE
Intervention: no peripheral block
Description: No peripheral block was applied. Standard multimodal analgesia method was applied.
Study NCT06125067 — intervention group
Intervention type: PROCEDURE
Intervention: Fascia Iliaca Compartment Block
Description: Fascia Iliaca Compartment Block is performed with the patient in a supine position. A high-frequency (6-14 MHz) linear ultrasound probe is positioned transversely to locate the femoral artery in the inguinal crease. The hyperechoic femoral nerve is usually visualized lateral to the femoral artery, between the iliopsoas and fascia iliaca. The probe is manoeuvred in a cranial and caudal direction to capture high-quality images of the femoral nerve and fascia iliaca. Identification of the triangular-shaped sartorius muscle and anterior superior iliac spine (ASIS) is achieved by lateral movement of the probe. Post-skin disinfection, the needle tip is directed just beneath the fascia iliaca. Local anaesthetic is administered following negative pressure aspiration into the area. The local anaesthetic spreads towards the femoral nerve medially and towards the iliac process laterally.
Study NCT06125067 — intervention group
Intervention type: PROCEDURE
Intervention: iPACK Block
Description: During the iPACK procedure, the patient assumes a supine position with the lower extremity flexed at the knee and abducted at the hip (in frog-leg position). The ultrasound transducer is placed in the lower third of the medial thigh, and then pushed backward and downward to visualize the gap between the popliteal artery and the femoral shaft, straight above the femoral condyles. After ensuring that the needle tip is placed 2 cm beyond the lateral border of the artery, local anaesthetic solution is administrated in divided doses to infiltrate the tissue space. The needle is then withdrawn after confirming negative aspiration.
Study NCT06354907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Kids' Empowerment Program
Description: The 12-session KEP provides support and information while teaching children self-management skills based on techniques derived from a combination of best, evidence-based practices (e.g., using elements of cognitive behavioral therapy, behavioral activation, brief behavioral activation, and interpersonal therapy. Adjustment is enhanced with a comprehensive approach that strengthens cognition (how to think about things), changes behavior (problem solving or planning actions), and focuses on emotions (identifying and expressing feelings), social relationships (peers, parents, siblings), and physical health (de-stressing, exercise). Group leaders follow a training manual with developmentally appropriate scripts, instructions for behavioral applications in (e.g., craft or game activities) and practice plans.
Study NCT06075810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBQ-167
Description: MBQ-167, an inhibitor of Rho GTPases Rac and Cdc42
Study NCT05886998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Heparin sodium (Generic, 5000 IU/ml ampoules)
Study NCT05886998 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% sodium chloride solution (normal saline)
Study NCT04082481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-988
Description: TAK-988 tablets.
Study NCT04082481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-988 Placebo
Description: TAK-988 placebo-matching tablets.
Study NCT06171282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant oncolytic herpes simplex virus type Ⅰ (R130)
Description: R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
Study NCT05548413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FamLit
Description: The FamLit (Family-focused and Literacy-sensitive strategy) is an interactive, multi-component intervention supported by the FamLit intervention Guide, including both spoken and printed materials written at a 4th-grade reading level for HF patients and their primary CPs.Three constructs guide the intervention, based on the Theory of Planned Behavior (TPB): 1) develop patient and CP positive attitudes through HF instruction and teach-back; 2) form positive subjective norms through coaching to improve patient and CP communication, support, and teamwork; and 3) increase perceived behavioral control through coaching and role-playing to empower patients and CPs to overcome individual barriers to adherence. This intervention also includes use of the SimpleMed+ electronic pillbox.
Study NCT05548413 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Participants in this group will talk with an interventionist to discuss general health. This intervention also includes use of the SimpleMed+ electronic pillbox.
Study NCT06126510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)
Description: VG161:1.0×10\^8PFU/day, intratumoral injection administration for 3 consecutive days, 28 days as a cycle